Comparative Pharmacology
Head-to-head clinical analysis: EMRELIS versus ZUPLENZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMRELIS versus ZUPLENZ.
EMRELIS vs ZUPLENZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Emrelis is a monoclonal antibody that inhibits the interaction between programmed cell death protein 1 (PD-1) and its ligands PD-L1 and PD-L2, thereby activating T-cell-mediated antitumor immune response.
Competitive serotonin 5-HT3 receptor antagonist; acts centrally on the chemoreceptor trigger zone and peripherally on GI vagal nerve terminals to inhibit emesis.
100 mg subcutaneously once weekly.
8 mg administered intraorally as a single dose 1 hour before chemotherapy; may repeat once if vomiting occurs within 30 minutes after initial dose.
None Documented
None Documented
12 hours (terminal); dosing interval adjusted in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life 3.5 hours; in hepatic impairment increases to 7-9 hours
Renal: 70% unchanged; fecal: 15%; biliary: 10%
Renal 70% unchanged, fecal 20% (including biliary metabolites), 10% metabolized
Category C
Category C
Antiemetic
Antiemetic